Glycemic Control System with Real-Time Insulin Dose Adjustment

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for glycemic control in diabetes management, particularly with basal insulin or insulin glargine, often result in under-dosing, leading to suboptimal blood sugar regulation and long-term health issues due to the lack of precise titration techniques.

Innovation Solution

A medical device and system that includes data storage, blood glucose measurement, and processing capabilities to calculate and adjust insulin doses based on real-time glucose data, allowing for personalized and flexible glycemic control through customizable algorithms and security validation for safe operation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If basal insulin or insulin glargine treatment is used with periodic blood glucose measurements, then glycemic control can be monitored, but under-dosing occurs leading to suboptimal blood sugar regulation

Engineering Contradiction:
Improveglycemic controlVSAvoiddose titration precision
Core Design Contradiction:
ReliabilityVSMeasurement precision

Solution Approach 1:

The system continuously monitors blood glucose levels and uses this feedback to automatically adjust insulin dosing. The processor receives blood glucose data from the sensor, compares it against target ranges, and modifies the insulin delivery rate accordingly, creating a closed-loop control system that eliminates under-dosing while maintaining reliable glycemic control

Inventive Principle:
Principle #23Feedback

Solution Approach 2:

The system enables patients to manage their own glycemic control through automated monitoring and dosing adjustments. The portable device performs self-testing of blood glucose levels and automatically calculates required insulin doses without requiring external intervention, empowering patients to achieve optimal glycemic control independently

Inventive Principle:
Principle #25Self-service

2Loss of information

If blood glucose values are monitored once or several times during the day, then information on treatment progress can be obtained, but the complexity of manual monitoring and titration increases

Engineering Contradiction:
Improvetreatment progress informationVSAvoidmonitoring system complexity
Core Design Contradiction:
Loss of informationVSDevice complexity

Solution Approach 1:

The system transitions from periodic discrete measurements to continuous real-time monitoring of blood glucose levels. The sensor continuously measures glucose concentration in interstitial fluid, providing an unbroken stream of data that captures the full dynamics of glycemic fluctuations throughout the day, eliminating information loss while simplifying the monitoring process

Inventive Principle:
Principle #20Continuity of useful action

Solution Approach 2:

The portable device integrates multiple functions into a single unit: blood glucose sensing, data processing, insulin dosing calculation, and patient interface. This multi-functional integration reduces overall system complexity by consolidating what would otherwise require separate devices and manual procedures into one unified automated system

Inventive Principle:
Principle #6Universality (Multi-functionality)

3Reliability

If the dose of basal insulin or insulin glargine is increased from initial dose to final dose over time, then glycemic control improves, but the time required for titration increases

Engineering Contradiction:
Improveglycemic controlVSAvoidtitration time
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The system performs preliminary calculations and predictions to determine the optimal insulin dose before actual administration. The processor analyzes current blood glucose levels, trends, and patient-specific parameters to pre-calculate the required dose adjustment, enabling immediate optimization without waiting for prolonged titration periods

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The system dynamically adjusts insulin dosing in real-time based on current glycemic conditions rather than following fixed static titration schedules. The processor continuously modifies the insulin delivery rate according to real-time blood glucose measurements and predicted future levels, accelerating the achievement of optimal glycemic control while maintaining safety

Inventive Principle:
Principle #15Dynamics

4Ease of operation

If patients perform self-titration with support from third party services, then patient empowerment increases, but the risk of dosing errors and safety issues increases

Engineering Contradiction:
Improvepatient empowermentVSAvoiddosing safety
Core Design Contradiction:
Ease of operationVSReliability

Solution Approach 1:

The processor acts as an intelligent intermediary between the patient and insulin dosing. It receives raw blood glucose data from the sensor, applies validated algorithms and clinical guidelines, and outputs precise dosing recommendations. This intermediary layer eliminates dosing errors by removing manual calculation and interpretation steps while maintaining patient empowerment through automated decision support

Inventive Principle:
Principle #24Intermediary (Mediator)

Data Source

PatentEP2393414B1Medical system and method for providing glycemic control based on glycemic response information
Publication Date: 2015.10.14 SANOFI AVENTIS DEUT GMBH
  • EP2393414B1 patent drawingFigure 1
  • EP2393414B1 patent drawingFigure 2
  • EP2393414B1 patent drawingFigure 3

AI summary

A medical device for providing information for glycemic control is provided, wherein the device comprises a storage unit arranged to store information on an initial dose of insulin and to store information on a blood glucose level measured after the initial dose of insulin was administered and after specific food was consumed, and a determining unit arranged to determine a subsequent dose of insulin to be administered before the specific food is consumed based at least on said information on the initial dose of insulin and said information on the blood glucose level.